MSB Trading - 2020, page-7996

We do not live in a utopia of fairness. A small example is below..

Hydroxychloroquine...

If hydroxychloroquine becomes an accepted treatment, several pharmaceutical companies stand to profit, including shareholders and senior executives with connections to the president. Mr. Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine.

Redmesivir...

In 2017, Trump nominated Joe Grogan66 to a top position at the U.S. Office of Management and Budget. Grogan spent five years as a lobbyist for Gilead—the pharmaceutical company that is infamous for its sky-high prices on a cure for hepatitis C.67 Since joining the administration, Grogan has led drug-pricing proposals and participated in Trump’s Drug Pricing and Innovation Working Group.”68 However, the working group has proposed pharma-friendly measures such as implementing monopoly rights outside of the United States, speeding up approval from the FDA for new drugs, and eliminating price cuts for hospitals in impoverished areas. "

So Mesoblast has an unfair playing field.